Origins
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from tuftsin, a naturally occurring immunomodulatory peptide fragment, with an added sequence to improve molecular stability.
Research areas
The published literature on Selank — much of it originating from Russian research institutions — concentrates on several themes:
- GABAergic signalling studies — in vitro work has examined how Selank interacts with GABA receptor expression and allosteric modulation.
- BDNF expression — rodent studies have measured changes in brain-derived neurotrophic factor levels in the hippocampus following administration.
- Enkephalin degradation — Selank has been reported to inhibit enkephalin-degrading enzymes in blood serum models.
- Immune-marker research — reflecting its tuftsin ancestry, some studies track cytokine profiles (notably IL-6) in cell models.
Selank and Semax
Selank is often discussed alongside Semax, another Russian-developed research peptide. While Semax derives from a fragment of ACTH and appears mainly in cognition-focused literature, Selank's research profile leans toward anxiety-model and immune-marker studies. Our Semax research overview is a useful companion read.
Regulatory status
Selank is not approved by the MHRA, FDA or EMA. Outside of research settings it has no authorised use in the UK. In laboratory contexts, researchers typically verify each batch with HPLC purity data — Selank from BioSupply UK ships with a full Certificate of Analysis.
Summary
Selank is a stable, well-characterised heptapeptide with a research literature focused on GABA signalling, BDNF expression and immune markers. As with most research peptides, robust human data is absent, and all use remains strictly laboratory-based.
All products mentioned are supplied strictly for laboratory research purposes only and are not intended for human consumption, diagnosis, or treatment. Nothing in this article constitutes medical advice.